Welcome to our dedicated page for Adma Biologics news (Ticker: ADMA), a resource for investors and traders seeking the latest updates and insights on Adma Biologics stock.
ADMA Biologics, Inc. (NASDAQ: ADMA) is a U.S.-based, end-to-end commercial biopharmaceutical company focused on specialty plasma-derived biologics and other specialty biologics for immunodeficient patients and individuals at risk for certain infectious diseases. The ADMA news feed on Stock Titan aggregates company-issued updates and market-moving announcements so readers can follow developments affecting the ADMA stock and its underlying business.
In its press releases, ADMA regularly reports on quarterly and annual financial results, including total revenue, GAAP net income, adjusted EBITDA and adjusted net income, as well as updates to its financial guidance. The company also issues news on operational milestones such as U.S. Food and Drug Administration (FDA) approvals for its production processes, progress with its yield enhancement production technology, and expansion of its U.S.-based manufacturing and plasma collection infrastructure.
Investors following ADMA news can expect coverage of commercial trends for its FDA-approved plasma-derived products ASCENIV, BIVIGAM and NABI-HB, including reported demand dynamics, payer coverage discussions, and distribution agreements. The company’s updates also address pipeline progress for SG-001, a pre-clinical hyperimmune globulin targeting Streptococcus pneumoniae, along with commentary on intellectual property, supply chain strategy and capital structure actions such as debt refinancing and share repurchase authorizations.
This news page is useful for tracking how ADMA communicates its financial outlook, operational initiatives and product performance over time. Readers interested in the ADMA stock can use the curated news flow to monitor earnings releases, regulatory and manufacturing updates, and other disclosures that the company furnishes through press releases and related filings.
ADMA Biologics received FDA approval for room temperature storage of its products ASCENIV and BIVIGAM for up to 4 weeks during the first 24 months of their 36-month shelf life. This approval enhances product accessibility for healthcare providers by alleviating supply chain constraints related to refrigeration. The room temperature storage capability is effective immediately, making these products commercially available to U.S. healthcare providers, thus improving inventory management and ease of administration.
ADMA Biologics, Inc. (Nasdaq:ADMA) has successfully closed its underwritten public offering, selling 20,979,020 shares at $2.86 per share, raising $69 million in total gross proceeds, including $9 million from an overallotment option. The funds will be allocated towards accelerating commercialization, completing plasma center buildouts, and FDA approvals, alongside general corporate purposes. Raymond James, Cantor Fitzgerald, and Mizuho acted as joint book-running managers. The offering was made under a previously filed 'shelf' registration statement.
ADMA Biologics, Inc. (Nasdaq:ADMA) has announced a public offering of 20,979,020 shares of its common stock at $2.86 per share, aiming for gross proceeds of approximately $60 million. The offering is expected to close on December 9, 2022, with a 30-day option for underwriters to purchase an additional 3,146,853 shares. Proceeds will support commercialization, production activities, plasma center buildout, and FDA approvals. Raymond James, Cantor Fitzgerald, and Mizuho Securities are managing the offering.
ADMA Biologics announced plans for an underwritten public offering of common stock, with underwriters receiving a 30-day option to purchase up to 15% more shares. The offering is contingent on market conditions and the exact size is yet to be determined. Proceeds will be allocated towards commercialization, plasma center expansion, FDA approvals, R&D, and working capital. This follows the company's strategic focus on developing specialty plasma-derived biologics. The offering will be filed under a previously effective registration statement with the SEC.
ADMA Biologics has announced preliminary estimates for its total revenue for Q4 and the full year of 2022. The company expects revenues for Q4 to be between $48 million and $50 million, representing over 85% year-over-year growth from $26.4 million in Q4 2021. For the entire year, projected revenues range from $152 million to $154 million. ADMA specializes in manufacturing and marketing plasma-derived biologics treating immunodeficient patients, further solidifying its position in the biopharmaceutical sector.
ADMA Biologics reported a 99% year-over-year revenue increase for Q3 2022, totaling $41.1 million, with gross profit rising to $9.7 million. The company has raised its FY 2022 revenue guidance to $145 million from $130 million. Gross margins are expected to improve as legacy lower-margin BIVIGAM inventory is exhausted. Operational losses narrowed to $14.9 million, down from $17.7 million in 2021. ADMA anticipates achieving profitability by early 2024, with long-term revenue targets set at approximately $250 million in 2024 and $300 million thereafter.
ADMA Biologics (Nasdaq: ADMA) announced it will release its financial results for Q3 2022 on November 9, 2022, after market close. Management will host a conference call at 4:30 p.m. ET the same day to discuss the results and company updates. ADMA specializes in manufacturing and marketing plasma-derived biologics for immunocompromised patients. It currently offers three FDA-approved products including ASCENIV™ and BIVIGAM® for primary immunodeficiency. The company operates a licensed facility in Boca Raton, Florida, and is committed to supporting niche patient populations.
ADMA Biologics announced FDA approval for its seventh plasma collection facility in Greensboro, North Carolina, enhancing its plasma supply self-sufficiency and revenue growth. This new facility, operational since Q1 2022, now complies with FDA standards for human source plasma collection. ADMA aims to achieve ten FDA-licensed plasma centers by the end of 2023, with this being the fourth approval this year. The facility features advanced technology to improve donor experience and is expected to employ 50 trained healthcare professionals.
ADMA Biologics reported strong second quarter 2022 results with total revenues of $33.9 million, a 90% year-over-year increase. Gross profit surged to $7.8 million, marking a 112% improvement from the previous quarter. The company narrowed net losses to $13.8 million, a 45% reduction from the first quarter. Full-year revenue guidance is set to exceed $130 million. Strategic expansions are ongoing, including plans for more FDA-licensed BioCenters. The company also anticipates achieving profitability by Q1 2024 with long-term revenue targets of up to $300 million.
ADMA Biologics, Inc. (Nasdaq: ADMA) will report its Q2 financial results for the period ended June 30, 2022, on August 10, 2022. The announcement includes a live conference call at 4:30 p.m. ET to discuss financial outcomes and company updates. ADMA specializes in manufacturing and marketing plasma-derived biologics, currently offering FDA-approved products for immunodeficient patients. The company operates a plasma fractionation facility in Boca Raton, Florida, and also runs FDA-approved plasma collection centers.